by Novartis Pharmaceuticals UK
with support from Aurora Healthcare Communications, The Clarion Portfolio and Salt
by AstraZeneca
with support from Real Chemistry
by Boehringer Ingelheim and Action for Pulmonary Fibrosis
with support from 11 London (supported by AVT)
by Norgine
with support from earthware
by Novartis UK
with support from Havas Life Medicom
by AstraZeneca
with support from Real Chemistry
Overuse of blue reliever (SABA) inhalers is a systemic and dangerous health problem. The situation prevails despite global asthma guidelines changing in 2019, urging doctors to stop treating symptoms solely with SABA inhalers.
Real Chemistry developed a first-of-its kind campaign for AstraZeneca to help patients and doctors assess SABA reliance and break the cycle of overuse. The creative campaign comes to life in both print and online and focuses on reaching patients at key ‘inhaler’ moments, driving them to seek more information and self-identify through an expert-developed self-assessment test.
The Break Over-Reliance entry took a very creative approach and had some great patient feedback, which resulted in intended actions. It had a good channel approach with some very high outcomes.
Entry deadline | 25 August 2023 |
Extended entry deadline | 1 September 2023* *additional fee applies |
Judging Day | 10 October 2023 |
Company/Team of the Year Interviews | 3 November 2023 |
PMEA Event | 22 November 2023 |